Daniel H Solomon1, Sara B Lee2, Agnes Zak2, Cassandra Corrigan2, Jenifer Agosti3, Asaf Bitton4, Leslie Harrold5, Elena Losina6, Bing Lu2, Ted Pincus7, Helga Radner8, Josef Smolen8, Jeffrey N Katz9, Liana Fraenkel10. 1. Division of Rheumatology, Brigham and Women׳s Hospital, Boston, MA. Electronic address: dsolomon@partners.org. 2. Division of Rheumatology, Brigham and Women׳s Hospital, Boston, MA. 3. JRA Consulting, North Andover, MA. 4. Division of General Medicine, Brigham and Women's Hospital, Boston, MA. 5. Department of Orthopaedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA. 6. Department of Orthopaedic Surgery, Brigham and Women׳s Hospital, Boston, MA. 7. Division of Rheumatology, Rush Medical School, Chicago, IL. 8. Division of Rheumatology, University of Vienna, Vienna, Austria. 9. Division of Rheumatology, Brigham and Women׳s Hospital, Boston, MA; Department of Orthopaedic Surgery, Brigham and Women׳s Hospital, Boston, MA. 10. Division of Rheumatology, Yale School of Medicine, West Haven Veterans Affairs Health System, New Haven, CT.
Abstract
BACKGROUND/ PURPOSE:Treat-to-target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various data sources suggest that its uptake in routine care in the US is suboptimal. Herein, we describe the design of a randomized controlled trial of a Learning Collaborative to facilitate implementation of TTT. METHODS: We recruited 11 rheumatology sites from across the US and randomized them into the following two groups: one received the Learning Collaborative intervention in Phase 1 (month 1-9) and the second formed a wait-list control group to receive the intervention in Phase 2 (months 10-18). The Learning Collaborative intervention was designed using the Model for Improvement, consisting of a Change Package with corresponding principles and action phases. Phase 1 intervention practices had nine learning sessions, collaborated using a web-based tool, and shared results of plan-do-study-act cycles and monthly improvement metrics collected at each practice. The wait-list control group sites had no intervention during Phase 1. The primary trial outcome is the implementation of TTT as measured by chart review, comparing the differences from baseline to end of Phase 1, between intervention and control sites. RESULTS: All intervention sites remained engaged in the Learning Collaborative throughout Phase 1, with a total of 38 providers participating. The primary trial outcome measures are currently being collected by the study team through medical record review. CONCLUSIONS: If the Learning Collaborative is an effective means for improving implementation of TTT, this strategy could serve as a way of implementing disseminating TTT more widely.
RCT Entities:
BACKGROUND/ PURPOSE: Treat-to-target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various data sources suggest that its uptake in routine care in the US is suboptimal. Herein, we describe the design of a randomized controlled trial of a Learning Collaborative to facilitate implementation of TTT. METHODS: We recruited 11 rheumatology sites from across the US and randomized them into the following two groups: one received the Learning Collaborative intervention in Phase 1 (month 1-9) and the second formed a wait-list control group to receive the intervention in Phase 2 (months 10-18). The Learning Collaborative intervention was designed using the Model for Improvement, consisting of a Change Package with corresponding principles and action phases. Phase 1 intervention practices had nine learning sessions, collaborated using a web-based tool, and shared results of plan-do-study-act cycles and monthly improvement metrics collected at each practice. The wait-list control group sites had no intervention during Phase 1. The primary trial outcome is the implementation of TTT as measured by chart review, comparing the differences from baseline to end of Phase 1, between intervention and control sites. RESULTS: All intervention sites remained engaged in the Learning Collaborative throughout Phase 1, with a total of 38 providers participating. The primary trial outcome measures are currently being collected by the study team through medical record review. CONCLUSIONS: If the Learning Collaborative is an effective means for improving implementation of TTT, this strategy could serve as a way of implementing disseminating TTT more widely.
Authors: Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo Journal: Arthritis Rheum Date: 2002-04
Authors: L H D van Tuyl; W F Lems; A E Voskuyl; P J S M Kerstens; P Garnero; B A C Dijkmans; M Boers Journal: Ann Rheum Dis Date: 2008-07-14 Impact factor: 19.103
Authors: Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen Journal: Ann Rheum Dis Date: 2010-04 Impact factor: 19.103
Authors: Michael J Taylor; Chris McNicholas; Chris Nicolay; Ara Darzi; Derek Bell; Julie E Reed Journal: BMJ Qual Saf Date: 2013-09-11 Impact factor: 7.035
Authors: Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2013-10-25 Impact factor: 19.103
Authors: Daniel H Solomon; Bing Lu; Zhi Yu; Cassandra Corrigan; Leslie R Harrold; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2018-10 Impact factor: 4.794
Authors: Daniel H Solomon; Elena Losina; Bing Lu; Agnes Zak; Cassandra Corrigan; Sara B Lee; Jenifer Agosti; Asaf Bitton; Leslie R Harrold; Theodore Pincus; Helga Radner; Zhi Yu; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz Journal: Arthritis Rheumatol Date: 2017-05-31 Impact factor: 10.995
Authors: Daniel H Solomon; Zhi Yu; Jeffrey N Katz; Asaf Bitton; Cassandra Corrigan; Liana Fraenkel; Leslie R Harrold; Josef S Smolen; Elena Losina; Bing Lu Journal: Arthritis Care Res (Hoboken) Date: 2019-07-19 Impact factor: 4.794
Authors: Maria I Danila; Lang Chen; Eric M Ruderman; Justin K Owensby; Ronan O'Beirne; Joshua A Melnick; Leslie R Harrold; David Curtis; W Benjamin Nowell; Jeffrey R Curtis Journal: ACR Open Rheumatol Date: 2021-12-27
Authors: Daniel H Solomon; Theodore Pincus; Nancy A Shadick; Jacklyn Stratton; Jack Ellrodt; Leah Santacroce; Jeffrey N Katz; Josef S Smolen Journal: Arthritis Care Res (Hoboken) Date: 2022-02-04 Impact factor: 5.178